September 2025 in “Figshare” Alopecia areata involves complex immune activity, mainly Th1, with potential benefits from broader immune treatments.
11 citations
,
March 2024 in “Cell and Tissue Research”
January 2026 in “Frontiers in Drug Discovery” Transforming skin disease treatment requires new strategies, better drug models, and patient-focused research.
25 citations
,
March 2021 in “Australasian Journal of Dermatology” Ustekinumab successfully treated a man's resistant skin condition when other treatments failed.
September 2025 in “Cell Reports” Skin stretching can improve vaccine delivery through hair follicles and boost immune response.
September 2017 in “Griffith Research Online (Griffith University, Queensland, Australia)” Blocking IL-17 can reduce joint inflammation in Ross River Virus infections.
August 2024 in “JAAD Case Reports” Upadacitinib successfully regrew hair in a child with alopecia universalis and specific genetic mutations.
59 citations
,
June 2023 in “Nature Aging” Blocking IL-17 signaling may reduce skin inflammation and delay aging.
6 citations
,
December 2022 in “Cold Spring Harbor Perspectives in Biology” Combining biochemical, immune, and mechanical signals can improve skin regeneration.
20 citations
,
June 2010 in “Genes and Immunity” Blood tests can help understand the genetic differences in people with alopecia areata, including how severe it is and if it's inherited.
19 citations
,
October 2008 in “Expert Review of Dermatology” EGF receptor is crucial for skin health and its inhibitors can cause skin rashes.
July 2024 in “Journal of Investigative Dermatology” 8 citations
,
January 2025 in “JADA Foundational Science” Photobiomodulation therapy can reduce pain and inflammation and help heal tissues, but more research is needed to improve its effectiveness and safety.
October 2022 in “JAAD international” Most patients with autoimmune blistering diseases experienced some hair loss, which may be underreported and linked to disease severity.
3 citations
,
April 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” ILC1 cells contribute to hair loss in alopecia areata.
12 citations
,
October 2024 in “Cell”
1 citations
,
November 2018 in “Therapeutic Delivery” New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.
October 2025 in “Australasian Journal of Dermatology” Bimekizumab effectively treated a man's chronic beard hair loss.
71 citations
,
October 2013 in “Experimental Dermatology” Vitiligo and alopecia areata may have similar causes despite their differences.
December 2024 in “International Journal of Dermatology” JAK inhibitors may help treat both alopecia areata and vitiligo, but more research is needed.
9 citations
,
March 2015 in “International reviews of immunology” Skin abnormalities can indicate immunodeficiency due to shared origins with the immune system.
1 citations
,
April 2020 in “Journal of the Endocrine Society” Immunotherapy with pembrolizumab significantly reduced cancer in a young woman with adrenocortical carcinoma.
January 2008 in “Projeto: revista mensal de arquitetura” Targeted cancer drugs can cause skin reactions, so dermatologists must manage these effects.
January 2016 in “Journal of Materials Chemistry B” Advancements in biomaterials and nanotechnology are improving medical applications like hair growth, bone regeneration, and cancer treatment.
Photobiomodulation effectively improves skin and hair conditions with minimal side effects.
3 citations
,
February 2023 in “Frontiers in Immunology” The IGRA test effectively detects past SARS-CoV-2 exposure, especially using nucleocapsid peptides.
2 citations
,
April 2025 in “Journal of Investigative Dermatology” February 2026 in “Advanced Sensor Research” Advanced technologies can improve understanding and monitoring of skin-brain interactions.
4 citations
,
January 2015 in “International Journal of Trichology” Transplanted hair follicles can change and adapt to new areas of the body, with the immune system possibly playing a role in this adjustment.
1 citations
,
January 2014 in “Hair therapy & transplantation” The combination therapy of PEG-IFN α-2a and Ribavirin can cause widespread hair loss and skin reactions.